David H. Ilson MD, PhDAttending Physician, Memorial Sloan Kettering Hospital; Professor of Medicine, Weill-Cornell Medical College, New York, New York
Dr. Ilson completed undergraduate training at the University of Connecticut. He entered an M.D., Ph.D. combined degree program at New York University and received a Masters and Ph.D. degree in Basic Science and M.D. Degree from NYU. He completed his internship and residency in internal medicine at Bellevue Hospital at NYU in New York. He then moved to Memorial Sloan-Kettering Cancer Center and completed a fellowship in medical oncology and hematology. He joined the staff in 1992, becoming a member of the GI Oncology Service in the Department of Medicine, under the direction of Dr. David Kelsen.
Dr. Ilson is now an attending physician at Memorial Sloan Kettering Hospital, and is professor of medicine at Weill-Cornell Medical College. His area of research interest is upper gastrointestinal cancer with a focus on esophageal cancer. His research has focused on the study of new agents in advanced disease, and the evaluation of novel agents in combined modality therapy programs in locally advanced disease. He sits on the GI committees of CALGB and RTOG, and the Upper GI Cancer Guidelines Committee of NCCN. He is chairman on the Intergroup Esophageal and Gastric Cancer Task Force Committee.
Recent Contributions to PracticeUpdate:
- Nivolumab Plus Chemotherapy or Ipilimumab in Gastro-Oesophageal Cancer
- FOLFIRI Plus Ramucirumab vs Paclitaxel Plus Ramucirumab as Second-Line Therapy for Advanced/Metastatic Gastroesophageal Adenocarcinoma With/Without Prior Docetaxel
- Nivolumab Combination Therapy in Patients With Advanced Esophageal SCC
- Neoadjuvant Chemoradiotherapy vs Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer
- Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer
- Assessment of Pembrolizumab for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer
- First-Line Nivolumab Plus Chemotherapy vs Chemotherapy Alone for Advanced Gastric, Gastro-Oesophageal Junction, and Oesophageal Adenocarcinoma
- Trastuzumab Deruxtecan in Patients With HER2-Expressing Metastatic Colorectal Cancer
- Effect of Celecoxib Added to Standard Adjuvant Therapy on Disease-Free Survival of Stage III Colon Cancer
- Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer